sellWeak cluster of 210b5-1 plan
Karen M. Anderson sold $2.1M of CNTA
Chief People Officer at Centessa Pharmaceuticals plc. 74,811 shares at an average of $28.19, traded Mar 16, 2026, filed Mar 18, 2026.
Warning score
33Value
$2.1M
74,811 shares
Holdings after
62,085
-59% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$2.1M at market
- +20Share of holdings soldSold 59% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001470831-26-000291, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | MOption exercise Ordinary Shares10b5-1 | +64,768 | $4.01 | $260k | 126,853 | Mar 18, 2026 |
| Mar 16, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -64,768 | $28.21 | $1.8M | 62,085 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Ordinary Shares10b5-1 | +10,043 | $4.01 | $40k | 72,128 | Mar 18, 2026 |
| Mar 17, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -10,043 | $28.10 | $282k | 62,085 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Share Option (right to buy)derivative10b5-1 | -64,768 | $0.00 | $0 | 85,043 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Share Option (right to buy)derivative10b5-1 | -10,043 | $0.00 | $0 | 75,000 | Mar 18, 2026 |
Related signals
Other insiders at Centessa Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Centessa Pharmaceuticals plc | Karen M. Anderson Chief People Officer | $1.2M 41,076 shares | -40% | |
| 19Weak | Centessa Pharmaceuticals plc | Gregory M Weinhoff Chief Business Officer | $720k 23,998 shares | -27% | |
| 33Weak | Centessa Pharmaceuticals plc | Karen M. Anderson Chief People Officer | $3.2M 120,029 shares | -66% | |
| 33Weak | Centessa Pharmaceuticals plc | Karen M. Anderson Chief People Officer | $3.2M 120,029 shares | -66% | |
| 48Moderate | Centessa Pharmaceuticals plc | Gregory M Weinhoff Chief Business Officer | $1.9M 73,196 shares | -53% | |
| 50Moderate | CNTAsell Centessa Pharmaceuticals plc | Iqbal J Hussain Chief Legal Officer | $1.0M 39,961 shares | -38% | |
| 14Weak | Centessa Pharmaceuticals plc | Mario Alberto Accardi President, Orexin Program | $288k 10,000 shares | -5% | |
| 0Weak | Centessa Pharmaceuticals plc | Mario Alberto Accardi President, Orexin Program | $300k 10,000 shares | -5% | |
| 18Weak | Centessa Pharmaceuticals plc | Tia L Bush Chief Technology & Quality Ofc | $1.1M 40,000 shares | -25% | |
| 0Weak | Centessa Pharmaceuticals plc | Iqbal J Hussain General Counsel | $166k 6,000 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.